ET
ADMA icon

Entropy Technologies’s ADMA Biologics ADMA Stock Holding History

Entropy Technologies’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,144
Closed -$222K – 860
2025
Q4 		$222K Buy
+12,144
New +$205K 0.01% 782
2025
Q2 		– Sell
-17,021
Closed -$338K – 758
2025
Q1 		$338K Buy
+17,021
New +$294K 0.03% 513
2024
Q4 		– Sell
-37,850
Closed -$757K – 700
2024
Q3 		$757K Buy
+37,850
New +$589K 0.08% 332

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Entropy Technologies's ADMA Position: Q1 2026 in Review

Entropy Technologies sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 12,144 shares — an estimated $222K sold.

Entropy Technologies first reported a position in ADMA in Q3 2024 and held it in 3 quarters. The position peaked at $757K in Q3 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Entropy Technologies reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Entropy Technologies sold 12,144 ADMA Biologics shares in Q1 2026, an estimated $222K.
  • Entropy Technologies first reported a position in ADMA Biologics in Q3 2024 and held it in 3 quarters.
  • Entropy Technologies's ADMA Biologics position peaked at $757K in Q3 2024.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.